Red Tree Management’s Contineum Therapeutics CTNM Stock Holding History

Red Tree Management’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.5M	Hold	638,158	–	–	7.1%	3
2026 Q1	$8.33M	Hold	638,158	–	–	7.45%	3
2025 Q4	$7.29M	Hold	638,158	–	–	6.69%	3
2025 Q3	$7.5M	Hold	638,158	–	–	9.04%	3
2025 Q2	$2.53M	Hold	638,158	–	–	3.46%	3
2025 Q1	$4.45M	Hold	638,158	–	–	4.81%	4
2024 Q4	$9.35M	Buy	+638,158	New	+$10.1M	6.15%	4

Other funds holding CTNM

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

IFG

Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

SCM

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

Torren Management San Diego, California $197M AUM

Red Tree Management's CTNM Position: Q2 2026 in Review

Red Tree Management held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 638,158 shares worth $10.5M. The position accounts for 7.1% of the portfolio, ranked #3.

Red Tree Management first reported a position in CTNM in Q4 2024 and has held it in 7 quarters since. 9 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

Red Tree Management held 638,158 shares of Contineum Therapeutics worth $10.5M as of Q2 2026.
Red Tree Management left its Contineum Therapeutics share count unchanged in Q2 2026.
Contineum Therapeutics made up 7.1% of Red Tree Management's portfolio in Q2 2026, its #3 holding.
Red Tree Management first reported a position in Contineum Therapeutics in Q4 2024 and has held it in 7 quarters since.
9 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Red Tree Management's 13F filing for Q2 2026, filed 22 Jul 2026.